APO-GLIMEPIRIDE 1 MG — DIN 02295377
GLIMEPIRIDE : 1 MG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is APO-GLIMEPIRIDE?
APO-GLIMEPIRIDE 1 MG contains GLIMEPIRIDE : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02295377, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 28-Nov-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is APO-GLIMEPIRIDE used for?
Adjunct to diet, exercise, and weight reduction to lower blood glucose in type 2 diabetes. May be used with metformin or insulin when monotherapy is inadequate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Glimepiride cost around the world?
Glimepiride is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 57 | 68 | SAR███.██ |
| Morocco | PPV (public price) | 11 | 67 | MAD███.██ |
| United States | acquisition | 3 | 54 | USD███.██ |
| South Africa | single exit price | 32 | 37 | ZAR███.██ |
| Bahrain | retail (max) | 10 | 28 | BHD███.██ |
| Australia | ex-manufacturer | 3 | 22 | AUD███.██ |
| United Arab Emirates | public | 21 | 21 | AED███.██ |
| Greece | producer price (ex-factory) | 21 | 21 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 9 | 16 | EUR███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
338 pack listings across 171 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Glimepiride pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Glimepiride in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Glimepiride, across 22 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 4 | 3 | SANDOZ GLIMEPIRIDE | Sourceable in Canada |
| APOTEX INC | 3 | 0 | APO-GLIMEPIRIDE | No marketed DIN |
| COBALT PHARMACEUTICALS COMPANY | 3 | 0 | CO GLIMEPIRIDE | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVO-GLIMEPIRIDE | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-GLIMEPIRIDE | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 3 | 0 | AMARYL | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | RATIO-GLIMEPIRIDE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions 1 mg, 2 mg, 4 mg strengths). |
| Storage | Not explicitly detailed in provided text (Table of Contents refers to page 21, but text ends earlier). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Glimepiride |
|---|---|
| ATC code | A10BB12 |
| AHFS class | 28:08.04.92 ; 12:12.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02295377 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2295377 |
| Brand name | APO-GLIMEPIRIDE |
| Generic / active ingredient | GLIMEPIRIDE : 1 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | A10BB12 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10BB |
| Current status | DORMANT |
| Status date | 28-Nov-2018 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administer once daily with breakfast or first main meal. Starting dose: 1 mg/day. Usual maintenance: 1-4 mg/day. Max: 8 mg/day. Titrate in increments of 1 mg at 1-2 week intervals.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Type 1 diabetes; known hypersensitivity to glimepiride, sulfonylureas, or sulfonamides; diabetic ketoacidosis; pregnant or breast-feeding women.
Warnings and precautions
Risk of severe, prolonged hypoglycemia. Increased cardiovascular mortality risk (caution in high-risk patients). Hemolytic anemia in G6PD-deficient patients. Serious hypersensitivity reactions.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 22 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| SANDOZ GLIMEPIRIDE | 4 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02269619 |
| SANDOZ GLIMEPIRIDE | 2 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02269597 |
| SANDOZ GLIMEPIRIDE | 1 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02269589 |
| AMARYL | 1 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02245272 |
| AMARYL | 4 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02245274 |
| AMARYL | 2 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02245273 |
| APO-GLIMEPIRIDE | 4 MG | TABLET | APOTEX INC | DORMANT | 02295393 |
| APO-GLIMEPIRIDE | 2 MG | TABLET | APOTEX INC | DORMANT | 02295385 |
| CO GLIMEPIRIDE | 2 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED POST MARKET | 02274256 |
| CO GLIMEPIRIDE | 1 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED POST MARKET | 02274248 |
2 · Same class — other molecules in ATC A10BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Gliclazide | AG-GLICLAZIDE MR · APO-GLICLAZIDE · APO-GLICLAZIDE MR · AVA-GLICLAZIDE · +17 more | 30 | 16 | Yes |
| Glibenclamide | APO GLYBURIDE TAB 2.5MG · APO GLYBURIDE TAB 5MG · AVA-GLYBURIDE · DIABETA · +24 more | 44 | 4 | Yes |
| Glimepiride | AMARYL · APO-GLIMEPIRIDE · CO GLIMEPIRIDE · NOVO-GLIMEPIRIDE · +3 more | 22 | 3 | Yes |
| Chlorpropamide | APO CHLORPROPAMIDE TAB 100MG · APO CHLORPROPAMIDE TAB 250MG · CHLORPROPAMIDE 100 TAB USP · CHLORPROPAMIDE TAB 250MG · +3 more | 8 | 0 | Not in Canada |
| Tolbutamide | MOBENOL TABLETS 500MG · NOVO-BUTAMIDE 500MG · ORINASE 0.5GM · ORINASE 1GM · +2 more | 7 | 0 | Not in Canada |
| Acetohexamide | DIMELOR TABLET 1843 500MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10BD | Combinations Of Oral Blood Glucose Lowering Drugs · Glimepiride And Rosiglitazone · Linagliptin And Empagliflozin · Metformin And Alogliptin · Metformin And Canagliflozin · +8 more | 123 | 67 |
| A10BH | Alogliptin · Linagliptin · Saxagliptin · Sitagliptin | 91 | 63 |
| A10BA | Metformin | 122 | 45 |
| A10BK | Canagliflozin · Dapagliflozin · Empagliflozin · Ertugliflozin | 42 | 30 |
| A10BX | Nateglinide · Repaglinide · Tirzepatide | 54 | 30 |
| A10BG | Pioglitazone · Rosiglitazone | 98 | 15 |
| A10BJ | Albiglutide · Dulaglutide · Exenatide · Liraglutide · Lixisenatide · +1 more | 34 | 13 |
| A10BF | Acarbose | 6 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-GLIMEPIRIDE called?
The same molecule, Glimepiride, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| GEPRID | Latin | Morocco |
| AMAREL | Latin | Morocco |
| ODIA | Latin | Morocco |
| ARX-GLIMEPIRIDE | Latin | Australia |
| Glimepiride Sandoz | Latin | Australia |
| GLIMEWIN | Latin | Morocco |
| GLIMEPIRIDE-WGR | Latin | Australia |
| G-PRIDE | Latin | Bahrain |
| AMARYL | Latin | Bahrain |
| DIAMERIL | Latin | Bahrain |
| GLEMA | Latin | Morocco |
| GLIM | Latin | Bahrain |
| GLYPRIDE | Latin | Bahrain |
| MILIPREL | Latin | Morocco |
| Diaglim | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.